1/20
Looks like no tags are added yet.
Natural products
- Compounds obtained from living organisms: plants, animals
- Can provide biolo active compounds & starting pts for drug discovery

Secondary (specialized) metabolites
- Compounds indirectly involved in core growth & reprod
- Help organisms interact w their enviro: defense, comp, signaling
- Biolo active โ source of drug leads
Searching for natural products
1. Get samples from a biolo source: plant, etc.
2. Prep extracts & screen for biolo activity
3. Isolate & purify active compounds
4. Determine chem structure
5. Confirm biolo activity
1a Biolo or trad knowledge can guide search
Challenges of natural prods as leads
- Active compounds can occur in v small amounts
- Hard to isolate & purify
- Chemically complex structures
- Challenging synth & mod
- Issues w supply & sustainable prod (ex: spongistatin)
Natural products must be scalable
- Drug development needs large & reliable supplies
- Production must be scalable, reproducible, econo practical, sustainable
- Possible approaches: fermentation, cultivation
Spongistatin (supply limits development)
Spongistatin 1 isolated from marine sponges
Very potent antitumor activity
Very low natural abundance โ major supply challenge
Requires an alternative, scalable source for further development

Rational drug design
Uses existing knowledge to design active molecules
Design or modify structures to improve desired properties
Info from enzyme substrates, natural inhibitors, etc.
Ex: captopril, acyclovir

Combinatorial chemistry (CC)
- Labo technique that rapidly creates & evaluates related compound libraries
- Systematically synth's combo's of diff chem building blocks
- Compounds may be prod & screened to identify promising hits
- Ex: Sorafenib (Nexavar)
Combinatorial search
1. Start w a common chem scaffold
2. Attach diff building blocks at diff positions
3. Generate a library of related compounds
4. Screen compounds individually or in mixtures (pools)
5. Active pool โ deconvolution
6. Identify active compound(s)
Sorafenib (Nexavar) - Combinatorial chemistry
Developed initially as a RAF kinase inhibitor
CC used to explore related compounds & identify an alt. core/scaffold
Promising compounds underwent further optimization
Ultimately developed into sorafenib, a multikinase inhibitor

Structure-based De Novo drug design
- Computer-assisted generation of new molecular structures
- Uses 3D structure of a biolo target
- Designs molecules to complement a binding site/pocket
- Target structures can come from x-ray crystallography, etc.
Process for structure-based De Novo drug design
1. 3D structure of biolo target
2. Identify active site
3. Analyze shape & chem int's
4. Computationally gen. candidate molecules
5. Dock & score predicted int's
6. Synth & exp. test promising compounds
What makes a useful lead?
- Confirmed biolo activity
- Some selectivity for desired target/effect
- Practical to synth
Structure-activity relationships (SAR) vs.
Structure-property relationships (SPR)
- SAR: How structural changes affect biolo activity
- SPR: How structural changes affect physicochem/drug-like properties
- Optimize multiple properties simultaneously: potency, selectivity, etc.
SAR process
1. Design structural mod's to the lead
2. Synth new analogues
3. Test biolo activity
4. Compare structure & activity
5. Identify features important for activity
6. Design next compounds using results
7. Repeat to improve lead (new lead)

SPR process
1. Lead โ molecule synth'd โ compound
2. Various tests performed (properties)
3. Compare structure & activity
4. Results help determine SPR
5. Important property or structural feature discovered โ New lead

Potency (SPR)
- Dose thats prods biolo actiivty
- Aim for lowest dose possible (low dose = high potency)
Selectivity (SPR)
- Selectivity ratio = concen for undesired activity รท concen for desired activity
- Greater selectivity = higher concen needed for undesired activity relative to desired activity

Drug-like properties
- Strong in vitro activity not enough
- Compound must reach action site at sufficient concen.
- Evaluate & optimize drug-like properties: solubility & permeability
- Computational methods to predict & prioritize compounds
Drug candidate
- Selected after lead optimization + for further development
- Practical synth & developmental pathway
- Backup compounds can be retained
Drug candidates have a well-characterized...
- Chem structure & properties
- BIolo activity
- Drug-like / ADME properties
- Prelim. safety profile